In Vivo CAR-T in 2026: What It Means for Your IND and Regulatory

"The companies engaging the FDA on in vivo CAR-T today are not simply navigating regulation. They are actively helping define it." AC

The In Vivo CAR-T Shift Is Already Happening

In vivo CAR-T platforms aim to deliver CAR-encoding material directly into immune cells inside the patient. No individualized manufacturing. No apheresis. No patient-specific clean room production. Potentially off-the-shelf administration, faster treatment timelines, expanded access, and outpatient delivery models.

The global cell and gene therapy market is projected to reach $33.5 billion by the end of 2026, with in vivo approaches representing the fastest-growing segment of new IND submissions. Several platform approaches are now advancing through early clinical development.

Each approach introduces fundamentally different safety considerations, manufacturing strategies, biodistribution concerns, immunogenicity profiles, and FDA regulatory questions. And none of them fit neatly into the traditional ex vivo CAR-T regulatory framework.

Why Autoimmune Disease May Accelerate the Entire Field

At the American Academy of Neurology Annual Meeting in Chicago in April 2026, Phase 2 data from the KYSA-6 trial demonstrated encouraging results for anti-CD19 CAR-T therapy in myasthenia gravis — low-grade cytokine release syndrome, no neurotoxicity, and meaningful functional improvements after a single dose. Separately, the AURORA Phase 3 trial continues to advance Descartes-08, an mRNA-based BCMA-targeting CAR-T for generalized MG, named by Nature Medicine as one of eleven clinical trials that will shape medicine in 2026.

Myasthenia gravis is the beachhead. The biology — antibody-mediated autoimmune pathology, a defined target population, measurable functional endpoints — makes it an ideal entry point. But the implications extend well beyond MG to lupus, rheumatoid arthritis, multiple sclerosis, and other antibody-mediated conditions where the underlying driver is a B cell population that has gone wrong.

The same platform logic that makes mRNA CAR-T attractive in MG — transient T cell programming, no permanent genome modification, outpatient potential — applies across that entire disease landscape. This is not a niche trend. It is potentially the next major expansion wave for engineered immune cell therapy.

The FDA Regulatory Questions Are Becoming More Complex

In vivo CAR-T changes foundational assumptions in regulatory science. When engineering occurs inside the patient, FDA reviewers must evaluate vector biodistribution, off-target transduction, in vivo potency, long-term persistence, immunogenicity, manufacturing comparability, and product classification simultaneously.

The central regulatory challenge is this: the therapeutic product is effectively being manufactured inside the patient. That changes everything. Traditional ex vivo frameworks do not fully address in situ cellular engineering, hybrid vector-plus-cell mechanisms, dynamic potency characterization, or platform-level manufacturing control.

FDA has not yet issued a dedicated in vivo CAR-T guidance framework. However, recent agency interactions strongly suggest movement toward process-and-mechanism-focused regulation — earlier CMC maturity expectations, stronger mechanistic rationale requirements, deeper biodistribution characterization, and greater emphasis on platform understanding starting at IND submission.

Five Strategic Questions Every In Vivo CAR-T Program Must Answer Before IND Submission

1. How will you characterize biodistribution?

When genetic engineering occurs inside the body, FDA will scrutinize where the delivery vehicle travels, what cells are transduced beyond T cells, and whether unintended tissues are affected. Biodistribution is no longer a secondary toxicology question — it becomes a primary regulatory discussion that shapes your Phase I dose selection and stopping rules.

2. How will you demonstrate manufacturing comparability?

In vivo programs may simplify logistics but they do not simplify regulatory scrutiny. FDA will still expect robust potency assays, lot consistency documentation, release characterization, and platform reproducibility. For many in vivo CAR-T approaches, regulatory precedent for potency assays remains limited — meaning you will be building the standard alongside FDA.

3. What is your CRS monitoring strategy?

Early in vivo data suggests potentially lower cytokine release syndrome rates compared with ex vivo CAR-T. But small Phase I datasets are not sufficient for regulators to assume reduced monitoring requirements. The REMS framework built around ex vivo CAR-T was developed over years of accumulated data. Your in vivo program needs its own proactive safety framework.

4. What is the correct regulatory classification?

Depending on platform design, an in vivo CAR-T product may involve biologic regulation, combination product considerations, vector-specific oversight, or multi-center FDA review pathways. This affects which FDA center reviews your application, which guidances apply, your IND package expectations, and your entire CMC structure. For highly novel platforms, classification ambiguity is one of the most costly sources of IND delay.

5. How will you define durable clinical response?

In autoimmune CAR-T, questions around immune reset and long-term response durability are becoming increasingly important. What does durable response look like at 18 months in a single-infusion program? FDA will want a pre-specified answer, and in the absence of established precedent, you will be building that definition collaboratively with the agency. That is an opportunity — but only if you arrive prepared.

The Breakthrough Prize Lesson — What History Teaches Us About Regulatory Timing

On April 18, 2026, the Breakthrough Prize in Life Sciences was awarded to the researchers whose foundational work gave us the first approved gene therapies for sickle cell disease, beta-thalassemia, and inherited blindness. Stuart Orkin, Swee Lay Thein, Jean Bennett, Katherine High, and Albert Maguire were recognized for discoveries that built the regulatory and clinical architecture that hundreds of subsequent gene therapy trials now stand on.

Both programs took decades from discovery to approval. Not because the science was slow — because the regulatory infrastructure did not yet exist for products of that novelty. The teams that succeeded were the ones that engaged FDA early, often, and specifically. They shaped the guidance. They built the data packages that gave FDA a basis for decisions it had never made before.

The teams building in vivo CAR-T programs in 2026 are in the same position. The science is ahead of the regulatory infrastructure. The founders who engage FDA now — at the INTERACT stage, at the pre-IND stage, before the protocol is locked — will shape the norms that everyone else follows for the next decade.